[go: up one dir, main page]

FR11C0016I1 - - Google Patents

Info

Publication number
FR11C0016I1
FR11C0016I1 FR11C0016C FR11C0016I1 FR 11C0016 I1 FR11C0016 I1 FR 11C0016I1 FR 11C0016 C FR11C0016 C FR 11C0016C FR 11C0016 I1 FR11C0016 I1 FR 11C0016I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0016(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9804211A external-priority patent/SE9804211D0/xx
Priority claimed from SE9901271A external-priority patent/SE9901271D0/xx
Application filed filed Critical
Publication of FR11C0016I1 publication Critical patent/FR11C0016I1/fr
Application granted granted Critical
Publication of FR11C0016I2 publication Critical patent/FR11C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR11C0016C 1998-12-04 2011-05-23 Nouveaux composes de triazolo(4,5-d)pyrimidine Active FR11C0016I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9804211A SE9804211D0 (sv) 1998-12-04 1998-12-04 Novel compounds
SE9901271A SE9901271D0 (sv) 1999-04-09 1999-04-09 Novel compounds
PCT/SE1999/002256 WO2000034283A1 (fr) 1998-12-04 1999-12-02 Nouveaux composes de triazolo(4,5-d)pyrimidine

Publications (2)

Publication Number Publication Date
FR11C0016I1 true FR11C0016I1 (fr) 2011-07-08
FR11C0016I2 FR11C0016I2 (fr) 2012-03-16

Family

ID=26663448

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0016C Active FR11C0016I2 (fr) 1998-12-04 2011-05-23 Nouveaux composes de triazolo(4,5-d)pyrimidine

Country Status (36)

Country Link
US (12) USRE46276E1 (fr)
EP (5) EP1386909A1 (fr)
JP (4) JP4202607B2 (fr)
KR (4) KR100776484B1 (fr)
CN (1) CN1128801C (fr)
AR (3) AR023920A1 (fr)
AT (3) ATE261970T1 (fr)
AU (1) AU766618B2 (fr)
BR (1) BRPI9915883B8 (fr)
CA (1) CA2351709C (fr)
CY (3) CY1110501T1 (fr)
CZ (3) CZ300280B6 (fr)
DE (4) DE122011100004I1 (fr)
DK (3) DK1386921T3 (fr)
EG (1) EG24814A (fr)
ES (3) ES2318081T3 (fr)
FR (1) FR11C0016I2 (fr)
HK (3) HK1061246A1 (fr)
HU (2) HU228589B1 (fr)
ID (1) ID29927A (fr)
IL (6) IL143232A0 (fr)
LT (1) LTPA2011004I1 (fr)
LU (1) LU91819I2 (fr)
MY (1) MY121867A (fr)
NO (3) NO319806B1 (fr)
NZ (1) NZ511778A (fr)
PL (1) PL201283B1 (fr)
PT (2) PT1386921E (fr)
RU (3) RU2317990C2 (fr)
SA (1) SA99200848B1 (fr)
SI (3) SI1135391T1 (fr)
SK (1) SK286007B6 (fr)
TR (1) TR200101567T2 (fr)
TW (1) TWI229674B (fr)
WO (1) WO2000034283A1 (fr)
ZA (1) ZA200104094B (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
MXPA06000675A (es) 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
SE0400873D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
JPWO2007020935A1 (ja) * 2005-08-17 2009-02-26 小野薬品工業株式会社 Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (fr) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions pour administration orale comprenant un dérivé de triazolo [4, 5] pyrimidine
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
CN102149716A (zh) * 2008-09-09 2011-08-10 阿斯利康(瑞典)有限公司 制备[1S-[1α,2α,3β(1S*，2R*),5β]]-3-[7-[2-(3,4-二氟苯基)-环丙氨基]-5-(丙硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇的方法及其中间体
WO2010043721A1 (fr) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Inhibiteurs d’oxydases et leur utilisation
WO2010084160A1 (fr) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
WO2011017108A2 (fr) 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Modulateurs cyclopropylés du récepteur p2y12
EP2305376A1 (fr) 2009-09-23 2011-04-06 Lonza Ltd. Procédé et catalyseur pour l'hydrogénation catalytique de composés de nitro aromatiques et hétéro-aromatiques
EP2480528B1 (fr) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Inhibiteurs de déméthylase-1 spécifique de la lysine et leur utilisation
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
CN102770434A (zh) 2009-12-03 2012-11-07 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
EP2633857B1 (fr) 2009-12-23 2015-08-12 ratiopharm GmbH Forme de dosage solide pharmaceutique de ticagrelor et de l'acide acétylsalicylique
AU2011216991A1 (en) 2010-02-16 2012-08-30 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106106A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour lutter contre les maladies et troubles associés à l'hepadnaviridae
EP2560947B1 (fr) 2010-04-19 2016-10-12 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase-1 spécifiques de la lysine, et leur utilisation
AU2011244023A1 (en) 2010-04-20 2012-10-25 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
BR112012033500A2 (pt) 2010-06-30 2016-11-29 Actavis Group Hf processo para a preparação de derivados de fenilciclopropilamina substiuídos, processo de vaso único para a preparação de derivados de fenilciclopropilamina substiuídos, formas de estado sólido de um sal de adição de ácido e processo para a preparação da forma de estado sólido de um sal de adição de ácido
CN104892525A (zh) 2010-07-29 2015-09-09 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
EP2598480B1 (fr) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (fr) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Procédés améliorés de préparation de (3ar,4s,6r,6as)-6-amino-2,2-diméthyltétrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol pur et son matériau de départ clé
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
CN103429576A (zh) * 2010-12-20 2013-12-04 阿特维斯集团公司 制备三唑并[4,5-d]嘧啶衍生物及其中间体的新方法
EP2712315B1 (fr) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour des troubles myéloprolifératifs
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
US9056838B2 (en) 2011-04-06 2015-06-16 Teva Pharmaceutical Industries Ltd. Intermediates and processes for preparing Ticagrelor
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CZ2011229A3 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
BR112013028936B1 (pt) 2011-05-13 2021-10-19 Astrazeneca Ab Processo para a preparação de benzil [(3as,4r,6s,6ar)-6-hidróxi-2,2-dimetiltetra-hidro- 3ahciclopenta[d]dioxol]-4-il]carbamato e compostos intermediários no processo
US20140329833A1 (en) * 2011-05-19 2014-11-06 Oryzon Genomics, S.A Lysine demethylase inhibitors for inflammatory diseases or conditions
WO2012156537A2 (fr) * 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase destinés au traitement de la thrombose et de maladies cardiovasculaires
WO2012164286A1 (fr) 2011-06-01 2012-12-06 Astrazeneca Ab Nouveaux co-cristaux de ticagrelor
WO2012172426A1 (fr) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Procédé amélioré de préparation de dérivés de cyclopentanamine et de leurs intermédiaires
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
US9221829B2 (en) 2011-09-14 2015-12-29 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2570405A1 (fr) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthèse de composés de triazolopyrimidines
US9487512B2 (en) 2011-10-20 2016-11-08 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
AU2012324805B2 (en) 2011-10-20 2017-04-13 Oryzon Genomics, S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP2771326B1 (fr) 2011-10-27 2017-12-20 LEK Pharmaceuticals d.d. Synthèse de composés de type triazolopyrimidine
EP2586773A1 (fr) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthèse de composés de type triazolopyrimidine
EP2589587A1 (fr) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthèse de cyclopropanes à substitution azote
MX2014006190A (es) 2011-11-30 2014-07-10 Actavis Group Ptc Ehf Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
EP2607355A1 (fr) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Synthèse de triazolopyrimidines
IN2014KN01491A (fr) * 2011-12-23 2015-10-23 Lek Pharmaceuticals
EP2628721A1 (fr) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthèse de l'acide 2-(3,4-difluorophényl) cyclopropanecarboxylique
WO2013144295A1 (fr) 2012-03-30 2013-10-03 Sandoz Ag Synthèse de dérivés de la 2-(3,4-difluorophényl)cyclopropanamine et de sels de celle-ci
EP2644590A1 (fr) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthèse de dérivés et sels de 2-(3,4-difluorophényl) cyclopropanamine
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2013163892A1 (fr) * 2012-05-02 2013-11-07 Sunshine Lake Pharma Co., Ltd. Nouveaux composés de triazolopyrimidine et leur procédé de préparation
CN102659815B (zh) * 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
EP2666771A1 (fr) 2012-05-24 2013-11-27 LEK Pharmaceuticals d.d. Synthèse de dérivés aminocyclopentanétriols
ITMI20121142A1 (it) * 2012-06-28 2013-12-29 Chemo Iberica Sa Processo chemoenzimatico per la produzione di fenil ciclopropilammine
EA024825B8 (ru) * 2012-06-29 2016-12-30 Зентива, К.С. Сокристалл тикагрелора с 3-гидрокси-2-нафтойной кислотой, способ его получения и применение
CN104640864B (zh) * 2012-07-04 2016-11-16 力奇制药公司 替格瑞洛与二价金属盐的加合物
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (fr) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Nouvelle forme amorphe de ticagrelor
IN2012MU03723A (fr) * 2012-12-31 2015-07-10 Megafine Pharma P Ltd
CN104045620B (zh) * 2013-03-12 2017-05-10 博瑞生物医药（苏州）股份有限公司 一种替卡格雷中间体的制备方法
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (fr) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
ITMI20130487A1 (it) 2013-03-29 2014-09-30 Chemo Res S L Alchilazione selettiva di ciclopentilalcoli
CN104098553B (zh) 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (fr) 2013-06-10 2014-12-17 Zentiva, a.s. Ticagrelor amorphe stabilisé
WO2014170026A1 (fr) 2013-04-18 2014-10-23 Zentiva, K.S. Ticagrelor amorphe stabilisé
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
EP2816043A1 (fr) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Particules Ticagrelor sphériques
WO2014206187A1 (fr) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 Procédé de préparation du ticagrelor et de ses intermédiaires
CN104250251B (zh) * 2013-06-25 2017-05-17 上海京新生物医药有限公司 一种替格瑞洛的制备方法
WO2015001489A1 (fr) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Compositions pharmaceutiques de ticagrélor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2015110952A1 (fr) 2014-01-21 2015-07-30 Wockhardt Limited Compositions pharmaceutiques orales solides comprenant du ticagrelor ou un sel de ce dernier
CN103992323B (zh) * 2014-04-18 2017-03-29 南通常佑药业科技有限公司 一种替格瑞洛的制备方法
WO2015162630A1 (fr) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Nouveaux procédés de préparation de triazolo[4,5-d]-pyrimidines, dont le ticagrelor, via de nouveaux intermédiaires et une nouvelle voie de synthèse
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3157907B1 (fr) 2014-06-18 2018-08-29 Flamma S.P.A. Procédé pour la préparation de composés de triazolo[4,5-d]pyrimidine cyclopentane
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
WO2016001851A1 (fr) * 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Préparation de ticagrélor
KR102594117B1 (ko) 2014-10-01 2023-10-26 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
CN105237540B (zh) * 2015-09-21 2017-10-03 南京正大天晴制药有限公司 一种替格瑞洛有关物质的制备方法、检测方法及用途
US20190002471A1 (en) 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
EA201892150A1 (ru) 2016-04-21 2019-05-31 Астразенека Аб Распадающиеся в полости рта таблетки
WO2018038265A1 (fr) * 2016-08-26 2018-03-01 田辺三菱製薬株式会社 Composé hétérocyclique azoté bicyclique
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
DK3292867T3 (da) * 2016-09-09 2019-07-22 Univ Liege Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
CN107814772A (zh) * 2017-11-24 2018-03-20 常州沃腾化工科技有限公司 4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法
EP3527571A1 (fr) * 2018-02-14 2019-08-21 Université de Liège Dérivés de pyrimidine pour la prévention et le traitement d'infections bactériennes
EA202190328A1 (ru) 2018-07-27 2021-07-01 КРКА, д.д., НОВО МЕСТО Фармацевтическая композиция, содержащая тикагрелор
CN109761785A (zh) * 2019-02-16 2019-05-17 安徽诺全药业有限公司 一种(1r，2r）-2-(3,4-二氟苯基)环丙烷羧酸的合成方法
GB201910656D0 (en) 2019-07-25 2019-09-11 Univ Liege New use of triazolo(4,5-d)Pyrimidine deerivatives
EP3919497A1 (fr) 2020-06-04 2021-12-08 Zaklady Farmaceutyczne Polpharma S.A. Procédé de préparation de ticagrelor
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides
WO2023213198A1 (fr) * 2022-05-04 2023-11-09 华东师范大学 Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106578A (en) 1960-09-16 1963-10-08 Smith Kline French Lab Nu-phenethyl-2-phenylcyclopropylamine derivatives
SE329623B (fr) 1967-06-08 1970-10-19 C F Boehringer Soehne Gmbh
DE1670265A1 (de) 1967-08-25 1971-01-28 Boehringer Mannheim Gmbh 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
US4016204A (en) 1975-10-31 1977-04-05 Nelson Research & Development Company Method of synthesis of trans-2-phenylcyclopropylamine
US4543255A (en) 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4742064A (en) 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
PT89482B (pt) 1988-01-20 1994-02-28 Univ Minnesota Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
CA2005192A1 (fr) 1988-12-12 1990-06-12 Peter M. Palese Methodes et composes pour la prophylaxie et le traitement des infections par le virus de l'hepatie b
US5110933A (en) 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
US5652366A (en) 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU665184B2 (en) 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
CA2107667A1 (fr) 1991-04-06 1992-10-07 Anthony Howard Ingall Analogues de l'atp
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5817660A (en) 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5338725A (en) 1992-06-30 1994-08-16 The Research Foundation Of The State University Of New York Anti-aggregatory agents for platelets
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
CN1042430C (zh) 1993-02-10 1999-03-10 英国阿斯特拉药品有限公司 N－烷基－2－取代的atp类似物、其制备方法和用途
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5831099A (en) 1995-03-10 1998-11-03 The United States Of America As Represented By The Secretary Of The Army Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
ATE217010T1 (de) 1995-07-11 2002-05-15 Astrazeneca Ab Inhibitoren der plättchenaggregation
WO1997009330A1 (fr) 1995-09-01 1997-03-13 Hokuriku Seiyaku Co., Ltd. Cristal d'hydrate et son procede de preparation
DE69632830T2 (de) 1995-11-21 2005-08-25 Euroscreen S.A. Rezeptor und dafür kodierendes nukleinsäuremolekül
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE213245T1 (de) * 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JPH10258654A (ja) 1997-03-18 1998-09-29 Delta Tsuuring:Kk リクライニングシート
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (es) 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
SE9702775D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9704709D0 (sv) 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
DE60020010T2 (de) 1999-06-21 2006-01-19 Yamamoto Chemicals, Inc., Yao Polymethinverbindungen, Verfahren zu deren Herstellung und deren Verwendung
SE9903759D0 (sv) 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
HUP0203371A3 (en) 1999-11-12 2005-02-28 Biogen Idec Ma Inc Cambridge Adenosine receptor antagonists and methods of making and using the same
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7040429B2 (en) 2001-10-10 2006-05-09 Invacare Corporation Wheelchair suspension
PL371259A1 (en) 2001-12-21 2005-06-13 Pfizer Products Inc. Directly compressible formulations of azithromycin
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
CN102149716A (zh) 2008-09-09 2011-08-10 阿斯利康(瑞典)有限公司 制备[1S-[1α,2α,3β(1S*，2R*),5β]]-3-[7-[2-(3,4-二氟苯基)-环丙氨基]-5-(丙硫基)-3H-1,2,3-三唑并[4,5-d]嘧啶-3-基]-5-(2-羟乙氧基)环戊烷-1,2-二醇的方法及其中间体
AU2011216991A1 (en) 2010-02-16 2012-08-30 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
BR112012033500A2 (pt) 2010-06-30 2016-11-29 Actavis Group Hf processo para a preparação de derivados de fenilciclopropilamina substiuídos, processo de vaso único para a preparação de derivados de fenilciclopropilamina substiuídos, formas de estado sólido de um sal de adição de ácido e processo para a preparação da forma de estado sólido de um sal de adição de ácido
CN103429576A (zh) 2010-12-20 2013-12-04 阿特维斯集团公司 制备三唑并[4,5-d]嘧啶衍生物及其中间体的新方法
US9056838B2 (en) 2011-04-06 2015-06-16 Teva Pharmaceutical Industries Ltd. Intermediates and processes for preparing Ticagrelor
WO2012172426A1 (fr) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Procédé amélioré de préparation de dérivés de cyclopentanamine et de leurs intermédiaires
MX2014006190A (es) 2011-11-30 2014-07-10 Actavis Group Ptc Ehf Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma.
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014083139A1 (fr) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Nouvelle forme amorphe de ticagrelor
IN2012MU03723A (fr) 2012-12-31 2015-07-10 Megafine Pharma P Ltd
WO2014118808A2 (fr) 2013-02-04 2014-08-07 Hetero Research Foundation Dispersion solide de ticagrelor
CN104098553B (zh) 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP3004113A2 (fr) 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Préparation de ticagrélor
WO2016001851A1 (fr) 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Préparation de ticagrélor
EP3730142A1 (fr) 2015-01-27 2020-10-28 Astrazeneca Méthode de traitement ou de prévention d'événements athérothrombotiques chez des patients présentant des antécédents d'infarctus du myocarde

Also Published As

Publication number Publication date
PL348724A1 (en) 2002-06-03
TR200101567T2 (tr) 2001-12-21
AU766618B2 (en) 2003-10-23
IL210398A0 (en) 2011-03-31
SI1135391T1 (en) 2004-08-31
KR20070007971A (ko) 2007-01-16
US20130109702A1 (en) 2013-05-02
US20030144305A1 (en) 2003-07-31
IL143232A0 (en) 2002-04-21
HK1061246A1 (en) 2004-09-10
CY1110501T1 (el) 2015-04-29
US6974868B2 (en) 2005-12-13
IL169013A (en) 2015-10-29
IL198040A0 (en) 2009-12-24
ZA200104094B (en) 2002-08-19
NO20012725D0 (no) 2001-06-01
ATE261970T1 (de) 2004-04-15
BRPI9915883B8 (pt) 2021-05-25
JP2002531567A (ja) 2002-09-24
EP1386917B1 (fr) 2011-06-22
SK7492001A3 (en) 2002-01-07
DK1386917T3 (da) 2011-08-29
LTC1135391I2 (lt) 2022-04-11
AR058967A2 (es) 2008-03-05
KR20010081054A (ko) 2001-08-25
SI1386917T1 (sl) 2011-09-30
CN1334816A (zh) 2002-02-06
HUS1300048I1 (hu) 2017-03-28
PL201283B1 (pl) 2009-03-31
RU2317990C2 (ru) 2008-02-27
RU2012121883A (ru) 2013-11-27
LU91819I2 (fr) 2011-08-01
CZ300280B6 (cs) 2009-04-08
EP1386909A1 (fr) 2004-02-04
CY2011005I2 (el) 2014-04-09
ATE418547T1 (de) 2009-01-15
AR072756A2 (es) 2010-09-22
KR100776484B1 (ko) 2007-11-28
JP2011016831A (ja) 2011-01-27
CZ295234B6 (cs) 2005-06-15
US20060025590A1 (en) 2006-02-02
NO2011007I1 (no) 2011-06-06
AU2016500A (en) 2000-06-26
IL183969A0 (en) 2009-02-11
KR20070086540A (ko) 2007-08-27
CY1111759T1 (el) 2015-10-07
DK1135391T3 (da) 2004-06-28
CA2351709C (fr) 2010-04-06
HK1039933B (zh) 2004-10-08
HUP0105081A3 (en) 2004-11-29
SA99200848B1 (ar) 2006-11-04
JP5043749B2 (ja) 2012-10-10
USRE46276E1 (en) 2017-01-17
RU2007133926A (ru) 2009-03-20
RU2593201C2 (ru) 2016-08-10
US20070265282A1 (en) 2007-11-15
EP2322513A2 (fr) 2011-05-18
US20140296258A1 (en) 2014-10-02
HU228589B1 (en) 2013-04-29
PT1386921E (pt) 2009-02-23
NZ511778A (en) 2003-10-31
JP5415383B2 (ja) 2014-02-12
MY121867A (en) 2006-02-28
ES2216623T3 (es) 2004-10-16
ES2318081T3 (es) 2009-05-01
EP1386917A1 (fr) 2004-02-04
NO2022007I1 (no) 2022-03-23
HK1039933A1 (en) 2002-05-17
DE69915675T2 (de) 2005-02-17
HK1061684A1 (en) 2004-09-30
EP1386921B1 (fr) 2008-12-24
BRPI9915883B1 (pt) 2015-08-18
US20100069408A1 (en) 2010-03-18
EP1135391A1 (fr) 2001-09-26
KR100822602B1 (ko) 2008-04-16
ATE513816T1 (de) 2011-07-15
ES2366902T3 (es) 2011-10-26
FR11C0016I2 (fr) 2012-03-16
IL143232A (en) 2008-12-29
US20150152111A1 (en) 2015-06-04
EP2322513A3 (fr) 2011-08-24
EP1386921A1 (fr) 2004-02-04
US6525060B1 (en) 2003-02-25
PT1135391E (pt) 2004-07-30
DK1386921T3 (da) 2009-03-23
HUP0105081A2 (hu) 2002-05-29
NO319806B1 (no) 2005-09-19
KR100764417B1 (ko) 2007-10-05
CY2011005I1 (el) 2014-04-09
NO2011007I2 (no) 2012-07-09
IL198040A (en) 2015-06-30
EP1135391B1 (fr) 2004-03-17
SI1386921T1 (sl) 2009-04-30
CN1128801C (zh) 2003-11-26
ID29927A (id) 2001-10-25
CZ300373B6 (cs) 2009-05-06
NO20012725L (no) 2001-07-31
TWI229674B (en) 2005-03-21
DE69915675D1 (de) 2004-04-22
SK286007B6 (sk) 2008-01-07
US7250419B2 (en) 2007-07-31
JP4202607B2 (ja) 2008-12-24
KR100742924B1 (ko) 2007-07-25
AR023920A1 (es) 2002-09-04
KR20060091056A (ko) 2006-08-17
DE69915675T4 (de) 2012-08-30
US20080214812A1 (en) 2008-09-04
JP2008266345A (ja) 2008-11-06
WO2000034283A1 (fr) 2000-06-15
BR9915883A (pt) 2001-08-21
US20120165348A1 (en) 2012-06-28
EG24814A (en) 2010-09-21
US20130072503A1 (en) 2013-03-21
LTPA2011004I1 (lt) 2022-04-11
IL183969A (en) 2011-03-31
DE69940171D1 (de) 2009-02-05
JP2007084551A (ja) 2007-04-05
CZ20011962A3 (cs) 2001-11-14
CA2351709A1 (fr) 2000-06-15
DE122011100004I1 (de) 2011-09-08

Similar Documents

Publication Publication Date Title
FR11C0016I1 (fr)
MX221116B (fr)
JP2638304C (fr)
JP2574686C (fr)
IN185396B (fr)
JP2593001C (fr)
JP2631561C (fr)
JP2632314C (fr)
JP2641598C (fr)
JP2576239C (fr)
JP2583481C (fr)
CN3074052S (fr)
CN3086159S (fr)
CN3077352S (fr)
CN3090186S (fr)
CN3073771S (fr)
CN3076976S (fr)
CN3090185S (fr)
CN3089347S (fr)
CN3089187S (fr)
CN3073190S (fr)
CN3076811S (fr)
CN3076419S (fr)
CN3072760S (fr)
CN3075591S (fr)